Introduction
============

Allogeneic hematopoietic cell transplantation (allo-HCT) has improved the prognosis of the patients with hematologic malignancies. Advances of conditioning regimens and immunosuppressive therapy contribute to the improvement of the prognosis. In addition, the introduction of unrelated bone marrow transplantation (UBMT) and cord blood transplantation (CBT) increased the chance to receive allo-HCT. These progresses have led to the result that some patients survive for more than a decade. Concomitantly, there have increased various problems to disturb the quality of life of long-term survivors after allo-HCT^[@B1],[@B2]^.

Chronic graft-versus-host disease (GVHD) is one of major problems for long-term survivors after allo-HCT, leading to reduced patient-reported quality of life and non-relapse mortality^[@B3]-[@B5]^.　 Risk factors for chronic GVHD include prior acute GVHD, donor peripheral blood stem-cell grafts, HLA disparity, female donors for male recipients, and recipient age^[@B6]^.　 Concerning the graft of allo-HCT, the incidence and severity of chronic GVHD are recently reported to be lower in CBT than UBMT patients^[@B7]^.

Acute GVHD is thought to be mediated primarily by mature donor T cells in the allogeneic stem cell product. By contrast, chronic GVHD is now considered to be more complex immune reaction. Both donor-derived effector T and B cells contribute to the pathology of chronic GVHD^[@B8],[@B9]^. In addition, regulatory elements within T and B cell lineages play important roles in the development and maintenance of immune tolerance after allo-HCT^[@B10],[@B11]^. Several reports have shown that the differences in immune reconstitution exist between the patients who received cord blood and other hematopoietic stem cell sources. In CBT patients, delayed recovery of T cells has been reported, by contrast, B cell numbers were higher compared to the patients received HLA-matched sibling or unrelated peripheral blood stem cell transplantation^[@B12]-[@B14]^. However, the observation duration was up to 2 years post allo-HCT. The differences in immune reconstitution more than 2 years after allo-HCT between CBT and UBMT have not been elucidated.

In this study, we investigated the differences of immune reconstitution between CBT and UBMT patients, who survive for more than 2 years after allo-HCT without relapse of underlying disease, in relation to the development of chronic GVHD in our institute.

MATERIALS AND METHODS
=====================

**Study design**

To determine whether the differences in immune reconstitution would exist between CBT and UBMT patients in long-survivors, we selected patients who had attended to our outpatient clinic for more than 2 years after allo-HCT and showed no symptoms of infections and relapse of underlying disease. Twenty-one patients who had received CBT (CBT group) and 20 patients who had received HLA-matched UBMT (UBMT group) from January 2002 to January 2014 were enrolled in this study. We collected peripheral blood for flow cytometric analysis to investigate immune reconstitution and clinical symptoms regarding allo-HCT at the time after allo-HCT described in duration in [Table 1](#T1){ref-type="table"} after informed consent was given. We examined whether the differences in the immune reconstitution between CBT and UBMT patients who survive for more than 2 years after allo-HCT and any relations to the development of cGVHD could exist. This study was approved by the ethical committee of our institute.

**Patient characteristics**

Patient characteristics concerning allo-HCT are listed in [Table 1](#T1){ref-type="table"}. Median age in CBT group (45 years old, range: 24-63) was significantly older than in UBMT group (38 years old, range: 20-56) (p\<0.01). But there was no significant difference in median duration from allo-HCT to the time, when the investigation was performed, between CBT (5.5 years, range: 2.4-13.1) and UBMT group (7.3 years, range: 2.1-14.1). Most of underlying disease were hematologic malignancies, only one patient in UBMT group was non-malignant disease (paroxysmal nocturnal hematuria/ aplastic anemia).

All of CBT were performed using cord blood which matched a minimum of 4 of 6 HLA loci to the patient at antigen level for HLA-A, HLA-B, and HLA-DRB1. In UBMT group, all patients received bone marrow but not peripheral blood stem cell from HLA-matched unrelated donor.

In 9 patients in CBT group and 12 patients in UBMT group, cyclophosphamide (60mg/kg x2) and total body irradiation (TBI) (3Gy x4) had been performed as conditioning regimen (myeloablative conditioning; MAC) ([Table 1](#T1){ref-type="table"}). In 12 patients in CBT group and 8 patients in UBMT group, various reduced intensity conditioning (RIC) had been conducted ([Table 1](#T1){ref-type="table"}). For the prophylaxis of GVHD, calcineurine inhibitor plus short-term methotrexate had been introduced into all of patients.

###### 

Clinical data in the patients who had received cord blood transplantation (CBT) and unrelated bone marrow transplantation (UBMT)

  CBT                                                              
  -------- ------- ---- --- ----- ---- ---------------- ---------- ------
  AML      NC      57   F   CB    \+   FLU+Mel+CA+TBI   CsA+sMTX   2.8
  ATLL     CR1     57   M   CB    \+   FLU+Mel+TBI      CsA+sMTX   3.4
  Ph+ALL   CR2     48   M   CB    \+   FLU+BU4+TBI      CsA+sMTX   2.4
  DLBCL    CR2     51   F   CB    \+   FLU+Mel+TBI      CsA+sMTX   2.4
  CMMoL    NC      40   M   CB    \+   CY+TBI           CsA+sMTX   3.9
  Ph+ALL   CR2     44   M   CB    \+   CY+TBI           CsA+sMTX   6.1
  FL       NC      56   M   CB    \+   FLU+Mel+TBI      CsA+sMTX   7.9
  ALL      CR1     32   F   CB    \+   CY+TBI           CsA+sMTX   9.5
  FL       CR3     51   M   CB    \+   FLU+Mel+TBI      CsA+sMTX   5.5
  ALL      CR1     41   M   CB    \+   FLU+Mel+TBI      CsA+sMTX   4.0
  AML      CR1     45   M   CB    \+   CY+AraC+TBI      CsA+sMTX   7.3
  AML      CR2     45   F   CB    \+   FLU+BU+TBI       CsA+sMTX   3.0
  Ph+ALL   CR1     39   F   CB    \-   CY+TBI           CsA+sMTX   10.8
  AML      CR2     44   F   CB    \+   CY+TBI           CsA+sMTX   7.1
  PTCL     NC      33   M   CB    \+   CY+TBI           CsA+sMTX   7.6
  AML      CR1     52   F   CB    \+   FLU+Mel+TBI      CsA+sMTX   3.5
  AML      CR1     38   F   CB    \+   CY+TBI           CsA+sMTX   2.1
  CML      CP1     24   M   CB    \+   CY+TBI           CsA+sMTX   13.1
  ATLL     CR1     41   F   CB    \+   FLU+Mel+TBI      CsA+sMTX   3.1
  MDS      RA      62   M   CB    \+   FLU+CA+Mel+TBI   CsA+sMTX   6.3
  Ph+ALL   CR1     63   M   CB    \+   FLU+Mel+TBI      CsA+sMTX   6.2
  UBMT                                                             
  AML      CR1     25   F   uBM   \+   CY+TBI           CsA+sMTX   8.8
  MDS      RAEB    54   M   uBM   \+   CY+TBI           CsA+sMTX   7.8
  AML      CR1     34   M   uBM   \+   CY+TBI           CsA+sMTX   3.4
  ALCL     CR2     56   M   uBM   \+   FLU+Mel+TBI      CsA+sMTX   4.3
  AML      CR2     48   F   uBM   \-   FLU+BU4+TBI      CsA+sMTX   5.0
  MM       sCR     39   F   uBM   \-   FLU+Mel+TBI      CsA+sMTX   2.1
  DLBCL    CR2     44   F   uBM   \+   FLU+BU2          CsA+sMTX   6.8
  FL       CR2     46   F   uBM   \+   FLU+Mel          CsA+sMTX   9.3
  MDS      RAEB2   26   M   uBM   \-   CY+TBI           CsA+sMTX   10.3
  AML      CR1     26   F   uBM   \+   CY+TBI           CsA+sMTX   13.6
  MDS      RAEB    38   M   uBM   \+   CY+TBI           CsA+sMTX   6.2
  AML      CR1     38   F   uBM   \+   CY+TBI           CsA+sMTX   8.0
  PNH/AA           39   F   uBM   \+   CY+FLU+ATG       CsA+sMTX   3.8
  AML      CR1     49   M   uBM   \+   CY+TBI           CsA+sMTX   10.2
  MDS      RAEB2   29   M   uBM   \+   CY+TBI           CsA+sMTX   8.0
  CML      BC      35   F   uBM   \+   CY+TBI           CsA+sMTX   11.7
  NHL      CR2     32   M   uBM   \+   CY+TBI           CsA+sMTX   14.1
  CML      CR2     38   M   uBM   \+   CY+TBI           CsA+sMTX   6.6
  AML      CR2     20   F   uBM   \+   FLU+BU2+TBI      Tac+sMTX   2.2
  DLBCL    NC      48   F   uBM   \+   FLU+BU2+TBI      CsA+sMTX   2.2

Allo-HCT; allogeneic hematopoietic cell transplantation, CMV; cytomegalovirus, GVHD; graft-versus-host disease, AML; acute myelogenous leukemia, ATLL; adult T cell leukemia/lymphoma, Ph+ALL; Philadelphia chromosome positive acute lymphoblastic leukemia, DLBCL; diffuse large B cell lymphoma, CMMoL; chronic myelomomocytic leukemia, FL; follicular lymphoma, ALL; acute lymphoblastic leukemia, PTCL; peripheral T cell lymphoma, CML; chronic myelogenous leukemia, MDS; myelodysplastic syndrome, ALCL; anaplastic large cell lymphoma, MM; multiple myeloma, PNH/AA; paroxysmal nocturnal hematuria/aplastic anemia, NHL; non-Hodgkin lymphoma, NC; non-complete remission, CR1; first complete remission, CR2; second complete remission, CR3; third complete remission, RA; refractory anemia, RAEB; refractory anemia with excess blast, sCR; stringent complete remission, BC; blastic crisis, CB; cord blood, UBMT; unrelated bone marrow transplantation, FLU; fludarabine, Mel; melphalan, CA; cytosine-arabinocyde, TBI; total body irradiation, BU; buslfan, CY; cyclophosphamide, CsA; cyclosporine A, sMTX; short-term methotrexate.

**Diagnosis of acute and chronic GVHD**

We collected clinical data from medical charts and diagnosed acute and chronic GVHD according to the previously described criteria^[@B15]^.

**Flow cytometry**

Aliquots of whole peripheral blood were stained with various mAbs according to the manufacturer's instructions. We had performed three-color flow cytometric analysis. mAbs used in this study were as follows: PC5-conjugated anti-CD4 mAb, PC5-conjugated anti-CD8 mAb, PE-conjugated anti-CD45RO mAb, FITC-conjugated anti-CD25 mAb, PE-conjugated anti-CD127 mAb, PC5-conjugated anti-CD19 mAb purchased from Beckman Coulter. FITC-conjugated anti-CD27 mAb and PE-conjugated anti-IgM mAb were purchased from Pharmingen.

In CD4+ or CD8+ cells, CD27+CD45RO- cells have been designated as naive T cell ([Figure 1A](#F1){ref-type="fig"}), and CD25+CD127-\~+- cells have been designated as regulatory T cell^[@B16]^ ([Figure 1B](#F1){ref-type="fig"}). In CD19+ cells, CD27- cells have been designated as naive B cell and CD27+ B cells as memory B cell ([Figure 1C](#F1){ref-type="fig"}). CD3-CD56+ cells have been determined as NK cell.

![Representative data of flow cytometric analysis of the peripheral blood](IJHOSCR-14-1-g001){#F1}

**Statistical analysis**

Immunologic parameters, described in Flow cytometry, were compared between the patients who received CBT and UBMT. In some investigation, immunologic parameters of the patients without versus with chronic GVHD were compared. A comparison between the two groups was performed using Mann-Whitney U test.

Results
=======

**Reconstitution in T cell between CBT and UBMT group**

We first examined the differences in the reconstitution of T cells between CBT and UBMT group. As shown in [Figure 2A](#F2){ref-type="fig"}, there was no significant difference in absolute number of CD4+ T cell, but significant differences were observed in absolute number of CD8+ cell and CD4/CD8 ratio between the two groups. Absolute cell number of CD8+ cell was significantly higher in UBMT patients ([Figure 2B](#F2){ref-type="fig"}). As a result, CD4/CD8 ration was significantly lower in UBMT patients ([Figure 2C](#F2){ref-type="fig"}). We next examined the ratio and cell count of subpopulations in T cells. In CD4+ and CD8+ cells, no significant difference in ratio and absolute cell number of naive cell (CD27+CD45RO-) was observed between the two groups as well as memory cell (CD27-CD45RO+) (data not shown). Furthermore, we have observed no significant difference in absolute cell number of regulatory T cell, which has been reported to be involved in the pathogenesis of chronic GVHD ([Figure 2D](#F2){ref-type="fig"}).

![Differences in T cell recovery between CBT and UBMT group Absolute count of CD4+ cell (A), CD8+ cell (B), CD4/CD8 ratio (C), and regulatory T cell (D) of peripheral blood were compared between CBT and UBMT group. \* indicates differences that are statistically significant (p\<0.05).](IJHOSCR-14-1-g002){#F2}

**Reconstitution in B cell and NK cell**

We next examined the recovery of B cells. As shown in [Figure 3A](#F3){ref-type="fig"}, absolute cell number of CD19+ cell in UBMT group was significantly lower than in CBT group (p\<0.05), although there was no significant difference in serum levels of immunoglobulins (IgG, IgA, and IgM) (data not shown). By contrast, no significant difference was observed in NK cell counts between the two groups ([Figure 3B](#F3){ref-type="fig"}). Absolute cell number of naive B cell (CD19+CD27-) was also lower in UBMT group without statistical significance (P=0.05) ([Figure 3C](#F3){ref-type="fig"}). In memory B cells (CD19+CD27+), absolute cell number tended to be lower in UBMT than CBT group without statistical significance ([Figure 3D](#F3){ref-type="fig"}, p=0.10). These results suggest that the differences in the reconstitution of B cells between CBT and UBMT patients at a long-term period after allo-HCT could exist.

![Differences in B cell recovery between CBT and UBMT group](IJHOSCR-14-1-g003){#F3}

**Complications after allo-HCT including chronic GVHD in CBT and UBMT group**

Complications after allo-HCT have been summarized in [Table 2](#T2){ref-type="table"}. Acute GVHD (grade II-IV) was observed in 7 and 6 patients in CBT and UBMT groups, respectively. CMV antigenemia was more frequently detected in CBT group but cleared in all of cases within 6 months after allo-HCT. In addition, bacterial infections such as sepsis and febrile neutropenia were more frequently complicated in CBT group, as described previously^[@B17],[@B18]^. Chronic GVHD was observed in 7 of 21 patients in CBT group and 8 of 20 patients in UBMT group. Three of 7 patients in CBT group and 5 of 8 patients in UBMT group were diagnosed as extended type of chronic GVHD. Continuation of immnosuppressive therapy has been required in 2 and 3 patients in CBT and UBMT group, respectively. We have found no clear difference in the frequency and the severity of chronic GVHD between the two groups in our institute, although the incidence of chronic GVHD has been reported to be higher in UBMT than CBT patients^[@B7]^.

To investigate whether the differences of immune reconstitution would exist between CBT and UBMT group in relation to the development of chronic GVHD, we further divided the patients into 4 groups according to the presence or absence of chronic GVHD as follows: the patients with cGVHD in CBT group (n=7), without cGVHD in CBT group (n=14), without cGVHD in UBMT group (n=12), with cGVHD in UBMT group (n=8).

**Immune reconstitution in T and B cells in relation to chronic GVHD**

We examined T cell recovery between 4 groups described above. There was no significant difference in CD4+ and CD8+ cell number and CD4/CD8 ratio between 4 groups (data not shown). As shown in [Figure 4A](#F4){ref-type="fig"} and [B](#F4){ref-type="fig"}, absolute cell number in peripheral blood of naive CD4+ but not naive CD8+ T cells was significantly lower in the patients with cGVHD in UBMT group. Absolute cell number of regulatory T cell was lower in the patients with cGVHD in UBMT group without statistical significance (p=0.08, [Figure 4C](#F4){ref-type="fig"}).

In B cells, absolute cell number of CD19+ cell in peripheral blood was higher in the patients with cGVHD in CBT group, but conversely lower in the patients with cGVHD in UBMT group, as shown in [Figure 4D](#F4){ref-type="fig"}.

These results suggest that there exist some differences in immune reconstitution of both T and B cells in relation to the development of chronic GVHD between CBT and UBMT group

![Comparison of immune recovery in T and B cells between the patients with and without chronic GVHD](IJHOSCR-14-1-g004){#F4}

**B cell subpopulations in relation to chronic GVHD among CBT and UBMT group**

To more precisely investigate the differences in B cell reconstitution between the two groups in relation to chronic GVHD, we next examined the subpopulation of B cells.

Both ratio and absolute cell number of naive B cell, which express CD19 but not CD27, were significantly higher in the patients with than without cGVHD in CBT group ([Figure 5A](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"}). By contrast, absolute cell number but not ratio of naive B cell was significantly lower in the patients with than without cGVHD in UBMT group ([Figure 5A](#F5){ref-type="fig"} and [D](#F5){ref-type="fig"}). Concerning memory B cells, ratio but not absolute cell number of CD19+CD27+ cell in peripheral blood was significantly lower in the patients with than without cGVHD in CBT group, while there was no significant difference in memory B cells between the patients with and without chronic GVHD in UBMT group ([Figure 5B](#F5){ref-type="fig"} and [E](#F5){ref-type="fig"}).

Regulatory B cells, which are also suggested to be involved in the pathogenesis of chronic GVHD, have been reported to be enriched in the IgM memory and transitional subsets^[@B11],[@B19]^. Therefore, we next examined the IgM memory B cells, designated as the cells which express CD19, CD27, and IgM on cell surface. As shown in [Figure 5C](#F5){ref-type="fig"} and [F](#F5){ref-type="fig"}, both ratio and absolute cell count were lower in the patients with cGVHD in CBT group, but the differences were not statistically significant. In UBMT group, we observed no significant difference in IgM memory B cells between the patients with and without chronic GVHD.

These results suggest that different immune reconstitution in T and B cells, which would be related to the development of chronic GVHD, could exist between CBT and UBMT patients.

![Comparison of immune recovery in B cell subpopulations between the patients with and without chronic GVHD](IJHOSCR-14-1-g005){#F5}

###### 

Complications after allo-HCT in the patients who had received cord blood transplantation (CBT) and unrelated bone marrow transplantation (UBMT)

  CBT                                                                                                                    
  --------- ---------------- ----------------- -------- --------------- ---------------------- ----------------- ------- ------------------
  AML       NC               57                F        I               \-                     \+                L       skin
  ATL       CR1              57                M        II              sepsis                 \+                L       skin
  Ph+ALL    CR2              48                M        I               FN                     \+                L       mouth
  DLBCL     CR2              51                F        I               sepsis                 \+                E       lung
  CMMoL     NC               40                M        II              Tbc                    \+                E       skin, liver
  Ph+ALL    CR2              44                M        0               FN                     \+                \-      
  FL        NC               56                M        0               FN                     \+                E       lung
  ALL       CR1              32                F        I               \-                     \+                \-      
  FL        CR3              51                M        0               FN                     \+                L       
  ALL       CR1              41                M        0               sepsis                 \+                \-      
  AML       CR1              45                M        0               \-                     \+                \-      
  AML       CR2              45                F        III             sepsis                 \-                \-      
  Ph+ALL    CR1              39                F        II              sepsis                 \+                \-      
  AML       CR2              44                F        II              sepsis                 \+                \-      
  PTCL      NC               33                M        II              sepsis                 \+                \-      
  AML       CR1              52                F        0               FN                     \+                \-      
  AML       CR1              38                F        II              \-                     \+                \-      
  CML       CP1              24                M        0               FN                     \+                \-      
  ATL       CR1              41                F        0               FN                     \+                \-      
  MDS       RA               62                M        I               hemorrhagic cystitis   \+                \-      
  Ph+ALL    CR1              63                M        I               \-                     \+                \-      
  UBMT                                                                                                                   
  Disease   Disease status   Age at allo-HCT   Gender   aGVHD (grade)   infection              CMV antigenemia   cGVHD   Sites of cGVHD
  AML       CR1              25                F        0               \-                     \+                \-      
  MDS       RAEB2            54                M        I               \-                     \+                L       mouth
  AML       CR1              34                M        II              FN                     \+                E       lung
  ALCL      CR2              56                M        II              sepsis                 \+                E       mouth, eye
  AML       CR2              48                F        0               sepsis                 \-                \-      
  MM        sCR              39                F        I               FN                     \-                \-      
  DLBCL     CR2              44                F        0               \-                     \-                \-      
  FL        CR2              46                F        I               pneumonia              \-                E       eye, lung
  MDS       RAEB2            26                M        0               FN                     \-                \-      
  AML       CR1              26                F        I               \-                     \+                \-      
  MDS       RAEB2            38                M        0               FN                     \-                \-      
  AML       CR1              38                F        I               \-                     \+                \-      
  PNH/AA                     39                F        0               pneumonia              \+                \-      
  AML       CR1              49                M        I               \-                     \+                \-      
  MDS       RAEB2            29                M        III             hemorrhagic cystitis   \+                L       skin
  CML       BC               35                F        I               FN                     \+                E       eye, skin, lung
  NHL       CR2              32                M        I               FN                     \+                \-      
  CML       CR2              38                M        III             \-                     \+                E       skin, mouth, eye
  AML       CR2              20                F        I               \-                     \-                L       skin, eye
  DLBCL     NC               48                F        III             FN                     \+                \-      

Allo-HCT; allogeneic hematopoietic cell transplantation, CMV; cytomegalovirus, GVHD; graft-versus-host disease, AML; acute myelogenous leukemia, ATLL; adult T cell leukemia/lymphoma, Ph+ALL; Philadelphia chromosome positive acute lymphoblastic leukemia, DLBCL; diffuse large B cell lymphoma, CMMoL; chronic myelomomocytic leukemia, FL; follicular lymphoma, ALL; acute lymphoblastic leukemia, PTCL; peripheral T cell lymphoma, CML; chronic myelogenous leukemia, MDS; myelodysplastic syndrome, ALCL; anaplastic large cell lymphoma, MM; multiple myeloma, PNH/AA; paroxysmal nocturnal hematuria/aplastic anemia, NHL; non-Hodgkin lymphoma, NC; non-complete remission, CR1; first complete remission, CR2; second complete remission, CR3; third complete remission, RA; refractory anemia, RAEB; refractory anemia with excess blast, sCR; stringent complete remission, BC; blastic crisis, CB; cord blood, UBMT; unrelated bone marrow transplantation, FN; febrile neutropenia, Tbc; tuberculosis, L; limited type, E; extensive type.

Discussion
==========

Recent advances of allo-HCT improve the prognosis of the patients with hematopoietic malignancies and result in the long-term survivors, while there have appeared several problems such as chronic GVHD in long-term survivors. Development of chronic GVHD results in the decrease of quality of life and increase non-relapse mortality in long-term survivors^[@B3]-[@B5]^. Recently, the pathogenesis of chronic GVHD has been elucidated^[@B8],[@B9]^. In the development of chronic GVHD, effector cells as well as regulatory cells have been reported to be involved^[@B10],[@B11],[@B19]^. Several reports have shown the differences in immune recovery between the patients transplanted with cord blood and peripheral blood stem cells from HLA-matched sibling or unrelated donor^[@B12]-[@B14]^. However, observation period for immune recovery was up to 2 years in these reports. It has been elucidated whether the differences of immune reconstitution between CBT and UBMT patients surviving more than 2 years would exist and relate to the development of chronic GVHD, although the incidence and the severity of chronic GVHD have been reported to be lower in CBT than UBMT patients among Japanese patients^[@B7]^.

In this study, we investigated the immunologic reconstitution by flow cytometric analysis in the patients who received CBT or UBMT, although the duration from allo-HCT to investigating time was varied in each patient. We observed several differences in both T- and B-cell lineages between the patients who received CBT and UBMT. Absolute cell number of CD8+ T cell was significantly higher in UBMT group, while no difference was observed in CD4+ T cell. As a result, the ratio of CD4/CD8 was significantly lower in UBMT group ([Figure 2](#F2){ref-type="fig"}). In respect to B cells, absolute cell number of B cell was significantly lower in UBMT group ([Figure 3A](#F3){ref-type="fig"}). In addition, absolute cell number of naive B cell was lower in UBMT group, but not significantly ([Figure 3C](#F3){ref-type="fig"}, p=0.05). These results suggest that different immune reconstitution between CBT and UBMT patients could exist even more than 2 years after allo-HCT.

Nine of 21 patients in CBT group and 12 of 20 patients in UBMT group had received MAC as conditioning regimen. The difference of conditioning regimen (MAC versus RIC) would possibly affect the immune reconstitution in the patients surviving more than 2 years after allo-HCT. However, Wike et al. investigated the effect of conditioning regimen on marrow damage and hematopoietic recovery in adult leukemia patients. They reported that MAC regimen including TBI leads to prolonged reduction in marrow cellularity, but does not show additional histological long-term injury and differences in immunologic recovery^[@B20]^. In addition, Geyer et al. also showed that immune cell subset recovery, immunoglobulin reconstitution, and the incidence of opportunistic infections did not differ significantly between MAC and RIC regimen in pediatric CBT cohort^[@B21]^. These results can suggest that differences of conditioning regimen would not affect immune reconstitution in our investigation.

Regarding the relation to the occurrence of chronic GVHD, several differences have found between the patients with and without chronic GVHD in both CBT and UBMT group.

In respect to T cells, absolute cell number of naive CD4+ T cell was significantly lower in the patients with chronic GVHD in UBMT group ([Figure 4A](#F4){ref-type="fig"}), while no significant difference was observed in naive CD8+ T cells and regulatory T cells ([Figure 4B](#F4){ref-type="fig"} and [C](#F4){ref-type="fig"}). Although regulatory T cells have been reported to be involved in the pathogenesis in chronic GVHD^[@B10]^, we have no significant difference between the patients with and without chronic GVHD in both groups. Although it has been observed that absolute cell number of regulatory T cell was lower in the patients with chronic GVHD in UBMT group, the difference was not statistically significant (p=0.08) ([Figure 4C](#F4){ref-type="fig"}). Immune reconstitution of T cells may be different between CBT and UBMT patients even in long-term survivors and might be related to the pathogenesis of chronic GVHD at least in UBMT patients.

Concerning B cells, significant differences of absolute cell number of CD19+ B cell between the patients with and without chronic GVHD were observed in both CBT and UBMT group ([Figure 4D](#F4){ref-type="fig"}). In addition, absolute cell number of naive B cell significantly differed between the patients with and without chronic GVHD in both groups. Absolute cell number of naive B cell was significantly higher in the patients with chronic GVHD in CBT group, while significantly lower in UBMT group ([Figure 5D](#F5){ref-type="fig"}). As we could not examine regulatory B cells in this study, we compared IgM memory B cells, which have been reported to contain regulatory B cells^[@B11]^, between CBT and UBMT patients in relation to the development of chronic GVHD. There was no significant difference between the patients with and without chronic GVHD in both groups, although IgM memory B cells were lower in the patients with chronic GVHD in CBT group, but not statistically significant. However, our results suggest that immune reconstitutions of B cells play important roles in the pathogenesis of chronic GVHD in both CBT and UBMT patients，being consistent to previous reports^[@B22],[@B23]^.

Taken together, our results suggest that the differences in immune reconstitution of T and B cells may exist between CBT and UBMT patients even in long-term survivors and might be related to the differences in the development of chronic GVHD between CBT and UBMT patients.

Treatment for chronic GVHD has been still difficult and not satisfactory, but new strategies for the treatment of chronic GVHD have been recently evolved^[@B24]-[@B26]^. Low-dose infusion of interleukin-2 to stimulate regulatory T cells has been reported to improve symptoms of chronic GVHD^[@B27]^. Infusion of rituximab targeting for B cells has also been reported to be effective to chronic GVHD^[@B26],[@B28]^. Investigating the immunological differences in the development of chronic GVHD between CBT and UBMT would provide the understanding of the pathogenesis of chronic GVHD and the clue to introduce more effective treatment modalities for chronic GVHD.

In this study, there is no significant difference in the observation period from allo-HCT between two groups, although age at allo-HCT was older in CBT group. Moreover, in all of patients, GVHD prophylaxis was calcineurine inhibitor and short-term methotrexate.

CONCLUSION
==========

Our results showed that the differences of immune reconstitution may exist between CBT and UBMT patients even in long- term survivors and might be correlated to the development of chronic GVHD, regardless of the small number of patients examined and the fact that longitudinal analysis was not used in our study. Studies in larger scale and more precise examinations of T and B cells would more clearly reveal the differences in the immune reconstitution and the roles of the pathogenesis of chronic GVHD in CBT and UBMT patients.
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